Consortium of Multiple Sclerosis Centers Annual Meeting

Properly Assessing Cognition in Patients With Multiple Sclerosis: John DeLuca, PhD

July 04, 2022

The senior vice president for research and training at the Kessler Foundation discussed the assessment of cognitive challenges among patients with multiple sclerosis and planning for treatment options when necessary. [WATCH TIME: 4 minutes]

Regularly Measuring Cognition in MS, and Treating Cognitive Issues: John DeLuca, PhD

July 01, 2022

The senior vice president for research and training at the Kessler Foundation spoke about the critical need to prioritize cognitive challenges among patients with multiple sclerosis, as it remains among the chief complaints. [WATCH TIME: 4 minutes]

CMSC 2022: Top Interviews and Key Takeaways

June 27, 2022

The NeurologyLive® team has compiled a roundup of our discussions with leaders in the multiple sclerosis field following the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).

Evobrutinib, BTK Inhibitors, and the Associations With Neurofilament Light: Jens Kuhle, MD, PhD

June 27, 2022

The head of the MS center at University Hospital Basel provided insight on the role of BTK inhibitors and how the multiple sclerosis community views the potential of neurofilament light as a key biomarker of neurodegeneration. [WATCH TIME: 3 minutes]

Exploiting Anti-CD3 Antibodies, Relevant Biomarkers in Progressive MS: Tanuja Chitnis, MD

June 24, 2022

The associate neurologist at Brigham and Women’s Hospital provided insight on the current state of promising targets in progressive MS and why anti-CD3 therapy might be a new consideration for future trials. [WATCH TIME: 2 minutes]

Effectiveness and Promise of Glatiramer Acetate Depot in Progressive Multiple Sclerosis: Ehud Marom

June 22, 2022

The president and chief executive officer of Mapi Pharma discussed the positive phase 2 findings of a new formulation of glatiramer acetate to treat progressive forms of MS, as well as the long-term plans for the drug. [WATCH TIME: 5 minutes]